Found: 9
Select item for more details and to access through your institution.
System xC- is a mediator of microglial function and its deletion slows symptoms in amyotrophic lateral sclerosis mice.
- Published in:
- 2015
- By:
- Publication type:
- journal article
System xC− is a mediator of microglial function and its deletion slows symptoms in amyotrophic lateral sclerosis mice.
- Published in:
- Brain: A Journal of Neurology, 2015, v. 138, n. 1, p. 53, doi. 10.1093/brain/awu312
- By:
- Publication type:
- Article
PAX3-FOXO1 uses its activation domain to recruit CBP/P300 and shape RNA Pol2 cluster distribution.
- Published in:
- Nature Communications, 2023, v. 14, n. 1, p. 1, doi. 10.1038/s41467-023-43780-4
- By:
- Publication type:
- Article
Reversible transitions between noradrenergic and mesenchymal tumor identities define cell plasticity in neuroblastoma.
- Published in:
- Nature Communications, 2023, v. 14, n. 1, p. 1, doi. 10.1038/s41467-023-38239-5
- By:
- Publication type:
- Article
Upregulation of the Mevalonate Pathway through EWSR1-FLI1/EGR2 Regulatory Axis Confers Ewing Cells Exquisite Sensitivity to Statins.
- Published in:
- Cancers, 2022, v. 14, n. 9, p. N.PAG, doi. 10.3390/cancers14092327
- By:
- Publication type:
- Article
Low-frequency variation near common germline susceptibility loci are associated with risk of Ewing sarcoma.
- Published in:
- PLoS ONE, 2020, v. 15, n. 9, p. 1, doi. 10.1371/journal.pone.0237792
- By:
- Publication type:
- Article
ERG transcription factors have a splicing regulatory function involving RBFOX2 that is altered in the EWS-FLI1 oncogenic fusion.
- Published in:
- Nucleic Acids Research, 2021, v. 49, n. 9, p. 5038, doi. 10.1093/nar/gkab305
- By:
- Publication type:
- Article
Genome-wide association study identifies multiple new loci associated with Ewing sarcoma susceptibility.
- Published in:
- Nature Communications, 2018, v. 9, n. 1, p. 1, doi. 10.1038/s41467-018-05537-2
- By:
- Publication type:
- Article
A biobank of pediatric patient-derived-xenograft models in cancer precision medicine trial MAPPYACTS for relapsed and refractory tumors.
- Published in:
- Communications Biology, 2023, v. 6, n. 1, p. 1, doi. 10.1038/s42003-023-05320-0
- By:
- Publication type:
- Article